TIS11D Lentiviral Activation Particles (h): sc-405406-LAC

ZFP36L2 encodes the RNA-binding protein TIS11D, a member of the tristetraprolin family that recognizes AU-rich elements in target mRNAs and promotes transcript deadenylation and decay. Through post-transcriptional control of cytokines, transcription factors, and cell-cycle regulators, TIS11D helps shape signaling outputs downstream of immune activation and differentiation programs, including pathways linked to NF-κB–dependent inflammation and lymphocyte development. Dysregulated ZFP36L2 activity has been associated with altered hematopoietic and T-cell homeostasis and has been studied in contexts of immune dysfunction and cancer biology where mRNA stability influences proliferation and lineage commitment.

TIS11D Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient ZFP36L2 upregulation across a broader range of human cell types.

TIS11D Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the ZFP36L2 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous TIS11D expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native ZFP36L2 genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.